司库奇尤单抗治疗中重度斑块状银屑病的临床疗效

Clinical efficacy of secuchiumab in the treatment of moderate to severe plaque psoriasis

目的分析司库奇尤单抗治疗中重度斑块状银屑病的临床疗效。方法选取某院2021年5月~2023年5月收治的60例中重度斑块状银屑病患者,根据随机数字表法分为两组。对照组(30例)采用常规治疗,研究组(30例)采用司库奇尤单抗注射液治疗。比较两组患者治疗前后炎症因子水平、银屑病皮损面积和严重程度指数(PASI)、皮肤病生活质量指数(DLQI)、瘙痒程度(VAS评分)及药物不良反应。结果治疗前,两组IL-17、IL-17A和IL-23水平、PASI评分、DLQI评分和VAS评分差异无统计学意义(P>0.05);与对照组相比,研究组治疗后IL-17、IL-17A、IL-23水平均更低,治疗4、8和16周后PASI评分、DLQI评分和VAS评分均更低(P<0.05);两组总不良反应发生率差异无统计学意义(P>0.05)。结论司库奇尤单抗治疗可有效降低中重度斑块状银屑病患者的炎症反应、皮损面积和严重程度、瘙痒程度,提高患者生活质量且具有较高的安全性。

Objective To analyze the clinical efficacy of secuchiumab in the treatment of moderate and severe plaque psoriasis.Methods 60 patients with moderate to severe plaque psoriasis admitted to a certain hospital from May 2021 to May 2023 were selected and divided into two groups according to random number table method.The control group(30 cases)received conventional treatment,and the study group(30 cases)received secuchiumab injection treatment.The levels of inflammatory factors,psoriasis lesion area and severity index(PASI),dermatological quality of life index(DLQI),pruritis degree(VAS score)between the two groups before and after treatment and adverse drug reactions were compared.Results Before treatment,there were no significant difference in IL-17,IL-17A and IL-23 levels,PASI scores,DLQI scores and VAS scores between the two groups(P>0.05).Compared with the control group,the levels of IL-17,IL-17A and IL-23 in the study group were lower after treatment,and the PASI scores,DLQI scores and VAS scores were lower after 4,8 and 16 weeks of treatment(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The treatment of secuchiumab can effectively reduce the inflammatory response,psoriasis lesion area and severity,and the pruritis degree in patients with moderate to severe plaque psoriasis,and improve the quality of life of patients with high safety.